New drug duo tested to fight back against rare liver disease
NCT ID NCT05239468
Summary
This study tested whether adding a new drug called bezafibrate to an existing one (obeticholic acid) could better control Primary Biliary Changitis (PBC), a chronic liver disease. It involved 72 adults with PBC who were already on standard treatment. The main goal was to see if the drug combination improved key liver blood test results over 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
-
Beth Israel Deaconess Medical Center Harvard Liver Research Center
Boston, Massachusetts, 02215, United States
-
DIM Clinical Privada
Ramos Mejía, Buenos Aires, Argentina
-
Facey Medical Group
Mission Hills, California, 91345, United States
-
Gastro One
Cordova, Tennessee, 38018, United States
-
Gastrointestinal Associates of Northeast Tennessee
Johnson City, Tennessee, 37604, United States
-
Hospital Italiano La Plata
La Plata, Buenos Aires, Argentina
-
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
-
Hospital Provincial del Centenario
Rosario, Argentina
-
Hospital Universitario Austral
Pilar, Argentina
-
Houston Methodist Cancer Center
Houston, Texas, 77030-2717, United States
-
Loyola University Medical Center
Maywood, Illinois, 60459, United States
-
Methodist Clinical Research Institute (CRI)
Dallas, Texas, 75203, United States
-
NYU Langone Medical Center
New York, New York, 10016-6402, United States
-
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
-
Pacific Gastroenterology Associates
Vancouver, British Columbia, V6Z 2K5, Canada
-
Piedmont Atlanta Hospital
Atlanta, Georgia, 30309, United States
-
Schiff Center for Liver Diseases / University of Miami
Miami, Florida, 33136, United States
-
Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado
Coronado, California, 92118, United States
-
Tampa General Medical Group
Tampa, Florida, 33606, United States
-
The Northern Alberta Clinical Trials and Research Centre
Edmonton, Alberta, T6G 287, Canada
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Montreal
Montreal, Quebec, Canada
-
Wake Endoscopy Center
Raleigh, North Carolina, 27607, United States
Conditions
Explore the condition pages connected to this study.